Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
Radiology and Oncology
Volume 57 (2023): Numero 3 (September 2023)
Accesso libero
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights
Xing Li
Xing Li
,
Kaida Liu
Kaida Liu
,
Lidong Xing
Lidong Xing
e
Boris Rubinsky
Boris Rubinsky
| 04 set 2023
Radiology and Oncology
Volume 57 (2023): Numero 3 (September 2023)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Review
Pubblicato online:
04 set 2023
Pagine:
279 - 291
Ricevuto:
20 lug 2023
Accettato:
04 ago 2023
DOI:
https://doi.org/10.2478/raon-2023-0044
Parole chiave
tumor treating fields
,
clinical applications of TTFields
,
mechanisms of action of TTFields
© 2023 Xing Li et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
The process of TTFields clinical trials on typical tumor types.
FIGURE 2.
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
FIGURE 3.
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
FIGURE 4.
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
FIGURE 5.
Researches on potential mechanisms of TTFields action.